Platelet Aggregation and Mental Stress Induced Myocardial Ischemia: Results from the REMIT Study

BACKGROUND—Mental stress-induced myocardial ischemia (MSIMI) is common in patients with ischemic heart disease (IHD) and associated with a poorer cardiovascular prognosis. Platelet © 2014, Published by Mosby, Inc. This manuscript version is made available under the CC BY-NC-ND 4.0 license. Address for Correspondence: Wei Jiang, MD, Professor of Psychiatry & Behavioral Sciences, Professor of Medicine, Duke University Medical Center, DUMC Box 3366, Durham, NC 27710, Office: 919-668-0762, Fax: 919-668-5271, [email protected]. Financial Disclosures: Jiang: Salary support through a NHLBI research grant; Boyle: Salary support through a NHLBI research grant. Ortel: Salary support through a NHLBI research grant; consultant for Instrumentation Laboratory, Boehringer Ingelheim, and Bayer and receiving grants or grants pending from GlaxoSmithKline, Eisai, Pfizer, Daiichi Sankyo, Instrumentation Laboratory, and Stago. Samad: Salary support through a National Heart, Lung, and Blood Institute (NHLBI) research grant, American Society of Echocardiography research grant. Velazquez: Salary support through a NHLBI research grant; research grants from Abbott Laboratories, Evalve, and Ikaria; receiving consulting fees from Boehringer Ingelheim, Gilead, and Novartis; named on a patent application to Duke University related to SSRI treatment for MSIMI. Harrison: None Kuhn: Salary support through a NIH grant. Wilson: Salary support through a National Heart, Lung, and Blood Institute (NHLBI) research grant Williams: Salary support through a NHLBI research grant; holds a US patent on the 5HTTLPR L allele for use as a marker of increased cardiovascular risk in stressed persons and that he is a founder and major stockholder of Williams LifeSkills Inc. Kuhn: support through a NHLBI research grant. O’Connor: Salary support through a NHLBI research grant; funding from Actelion Pharmaceuticals Ltd, Amgen Inc, Biscardia LLC, Faculty Connection, GE Healthcare, Ikaria, Novella Clinical Inc, Pfizer Inc, Pozen, and Roche Diagnostics; serving as a consultant for Novartis, Heartware, ResMed, Johnson & Johnson, Gilead, Critical Diagnostics, BG Medicine, Otsuka, Astellas, Cytokinetics, and Capricor; holds stock or stock options in Neurotronik/Interventional Autonomics Corporation; named on a patent application to Duke University related to selective serotonin reuptake inhibitor (SSRI) treatment for MSIMI; serves as a journal editor for the American College of Cardiology. Becker: Salary support through a NHLBI research grant; research grant support from Baxter, Bristol-Myers Squibb, Johnson & Johnson, and Regado Biosciences; receiving consulting/lecture fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Merck, Regado Biosciences, and Sanofi-Aventis. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. HHS Public Access Author manuscript Am Heart J. Author manuscript; available in PMC 2016 April 01. Published in final edited form as: Am Heart J. 2015 April ; 169(4): 496–507.e1. doi:10.1016/j.ahj.2014.12.002. A uhor M anscript